Association between comorbidities and disease activity in axial spondyloarthritis: results from the BSRBR-AS by Zhao, Sizheng Steven et al.
1 
 
Association between comorbidities and disease activity in axial spondyloarthritis: results from the 
BSRBR-AS 
Sizheng Steven Zhao1,2, Gareth T Jones3, Gary J Macfarlane3, David M Hughes4, Robert J Moots2,5, 
Nicola J Goodson2 
1 Musculoskeletal biology 
Institute of Life Course and Medical Sciences 




2 Department of Rheumatology 




3 Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group)  
School of Medicine Medical Sciences and Nutrition 




4 Department of Biostatistics 
Institute of Translational Medicine 




5 Faculty of Health, Social Care and Medicine 
Edge Hill University 





Dr Nicola J Goodson 











Objective. Whether comorbidities influence disease activity assessment in axial spondyloarthritis 
(axSpA) is unclear. Comorbidities inflate DAS28 in rheumatoid arthritis through the patient global 
score. We examined whether axSpA disease activity measures are differentially affected, and 
whether comorbidities inflate the AS disease activity score (ASDAS) through the patient global 
component.  
Methods. We used baseline data from the British Society for Rheumatology Biologics Register for AS, 
including 14 physician diagnosed comorbidities. Linear models were used to compare disease 
activity (BASDAI, spinal pain, ASDAS, ESR/CRP) according to comorbidity count, adjusted for age, 
gender, BMI, smoking, socioeconomic status, and education. The same models were used to 
examine whether patient global was associated with comorbidities, additionally adjusting for other 
ASDAS components. 
Results. 2043 participants were eligible for analysis (67% male, mean age 49 years); 44% had at least 
one comorbidity. Each additional comorbidity was associated with higher BASDAI by 0.40 units 
(95%CI 0.27 to 0.52) and spinal pain by 0.53 (95%CI 0.37 to 0.68). Effect size for ASDAS (0.09 units; 
95%CI 0.03 to 0.15) was not clinically significant. ESR and CRP were not associated with comorbidity 
count. Depression, heart failure and peptic ulcer were consistently associated with higher disease 
activity measures, but not CRP/ESR. Patient global was associated with comorbidity count, but not 
independently of other ASDAS components (p=0.75). 
Conclusion. Comorbidities were associated with higher patient reported disease activity in axSpA. 
Clinicians should be mindful of the potential impact of comorbidities on patient reported outcome 
measures and consider additionally collecting ASDAS when comorbidities are present. 
Keywords: axial spondylarthritis, ankylosing spondylitis, comorbidity, disease activity, patient global 
Key messages: 
1. Comorbidity count is associated with significantly higher disease activity measured by BASDAI but 
not ASDAS. 
2. Depression, peptic ulcer and heart failure are associated with higher disease activity, not with 
CRP/ESR. 




Axial spondyloarthritis (axSpA) is a chronic inflammatory disease causing pain and functional 
impairment [1]. Assessing axial disease activity presents unique challenges since the spine and 
sacroiliac joints – unlike peripheral joints – are not easily accessible for clinical examination. It has 
been suggested that traditional biomarkers of inflammation – CRP and ESR – do not always reflect 
the underlying disease activity [2]. Disease activity assessment has traditionally relied on patient-
reported outcome measures (PROMs); for example, eligibility to commence and continue biologics 
are defined using thresholds of BASDAI and spinal pain in the UK [3]. 
PROMs are important but subjective. Studies have shown that patient perspectives are more closely 
associated with function and fatigue, whereas physician assessments of disease activity with 
metrology and CRP [4]. The former may not be specific to axSpA disease activity; for example, 
cardiorespiratory diseases can significantly reduce function [5,6], while concurrent depression and 
fibromyalgia will influence fatigue [7]. 
ASDAS was developed to address some of these concerns [8,9]. ASDAS combines three questions 
from BASDAI (stiffness, back and peripheral symptoms) with CRP/ESR and the patient global score, 
analogous to the DAS28 for rheumatoid arthritis (RA). Unlike BASDAI, it has been shown to associate 
with radiographic progression [10]. However, whether ASDAS is robust to the influence of 
comorbidities compared to patient-reported disease activity has not been examined. In RA, 
comorbidity count inflates DAS28 through the patient global score, independently of swollen/tender 
joints and inflammatory markers [11]. It is unknown whether the same vulnerability exists for 
ASDAS. Understanding whether and how comorbidities influence assessment of disease activity is 
crucial given their high prevalent [12,13]. 
The aims of this study were to 1) compare whether measures of disease activity (BASDAI, spinal pain, 
ASDAS) and inflammation (CRP/ESR) are differentially influenced by comorbidities, 2) replicate these 
comparisons for other important measures of disease severity (fatigue, function and quality of life), 
and 3) examine whether the patient global component of ASDAS is influenced by comorbidities 





The British Society for Rheumatology Biologics Register for Ankylosing Spondylitis (BSRBR-AS) is a 
UK-wide prospective cohort study of biologics-naïve patients fulfilling the ASAS criteria for axial SpA. 
Patients were recruited between December 2012 and December 2017 into two groups: a “biologic” 
group (those starting biologic DMARDs (bDMARDs)) and a “non-biologic” group (those not). The 
study protocol [14] and cohort characteristics have been previously published [15]. This analysis 
focused on baseline (cross-sectional) data before the biologic group started bDMARDs. This analysis 
used the study dataset of December 2018. 
Participating centres obtained physician diagnosed comorbidity data from medical records. The list 
of comorbidities included: myocardial infarction, angina, heart failure, stroke, hypertension, 
diabetes, asthma, chronic obstructive pulmonary disease (COPD), peptic ulcer disease, liver disease, 
renal disease, depression, cancer, tuberculosis (TB) and demyelinating disease. These conditions 
were selected through a consensus meeting of clinicians and researchers, based on commonly 
recorded comorbidities in routine practice. Comorbidity status was defined at baseline. Myocardial 
infarction and angina were combined as ischaemic heart disease (IHD) for this analysis. Extra-
articular manifestations of axSpA (uveitis, psoriasis and IBD) were considered disease features rather 
than comorbidities, given that they share pathogenesis with axSpA and form part of the 
classification criteria (thereby determining study inclusion) [16,17]. 
Questionnaires collected PROMs, highest educational attainment, and smoking status. Baseline visits 
and questionnaires did not necessarily coincide; we included questionnaires within one year before 
or after the baseline visit for the non-biologic group, and one year before to seven days after for the 
biologic group (the “eligible window”). Disease activity was assessed using the Bath AS Disease 
Activity Index (BASDAI), AS Disease Activity Score (ASDAS), spinal pain numerical rating scale (NRS); 
inflammation using CRP (mg/dl) and ESR (mm/hr); functional impairment using Bath AS Functional 
(BASFI) and Metrology Indices (BASMI); fatigue using the Chalder Fatigue Scale Likert scale (CFQ) 
which has a range of 0 to 33 with higher scores indicating greater levels of fatigue [18]; and quality 
of life using the AS quality of life questionnaire (ASQoL) which has a range of 0 to 18 with higher 
scores indicating poorer quality of life. All patient reported indices were collected at the same time; 
They are collectively referred to as measures of disease severity throughout the text. To provide 
context for interpretation of results, minimal clinically important difference in BASDAI is around 1 
unit, pain NRS 1.6 units, ASDAS 1.1 units, BASFI 0.6 units, ASQoL (meaningful deterioration) 1 unit, 
CFQ 2.3-3.3 units, and undefined for the remaining indices [19–23].  
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ASDAS was calculated using the formula 0.12*Back Pain + 0.06*Duration of Morning Stiffness + 
0.07*Peripheral Pain/Swelling + 0.11*Patient Global + 0.58*Ln(CRP+1); that is, questions 2, 3 and 6 
from BASDAI, plus patient global which asks “How active was your spondylitis on average during the 
last week?” [8,9] Where CRP was not available, ASDAS was calculated using ESR [8,9]. 
Covariates were determined a priori based on discussion and causal diagrams [24], including age, 
gender (female as referent), BMI, smoking status (ever/never), socioeconomic status (as continuous 
variable) and educational attainment (as dummy variables). Socioeconomic status was approximated 
using post-code derived Index of Multiple Deprivation (IMD) that related to the specific country of 
residence within the UK; quintile 1 representing the top 20% most deprived areas and quintile 5 the 
least deprived [17, 18]. Smoking was categorised as ever and never, since comorbidities will 
influence smoking cessation behaviour. Similarly, use of NSAIDs in the past 6 months is an 
intermediate variable, thus excluded as a covariate (see online supplementary materials for causal 
diagrams and justification). 
Ethical approval was obtained from the National Research Ethics Service Committee North East—
County Durham and Tees Valley (reference 11/NE/0374) and informed consent was obtained from 
all participants. 
Analysis 
Descriptive statistics were used to compare participants with and without comorbidities (t- and 
Wilcoxon rank-sum tests for continuous variables, Fishers exact test for categorical). The count of 14 
comorbidities was entered as a continuous variable into linear models to describe its association 
with each disease severity measure, adjusting for the above covariates. To test for non-linear 
relationships and to facilitate interpretation, we also categorised comorbidity count as 0, 1, 2 or ≥3 
(only 32 patients (1.6%) had 4 or more comorbidities). CRP and ESR were transformed using 
ln(CRP+1) and ln(ESR).  
We also examined the independent contribution of individual comorbidities to each disease severity 
measure by adding all 14 comorbidities into linear models, adjusting for the same covariates. 
Individual conditions may be closely related to others (e.g., hypertension and IHD); we therefore 
examined variance inflation factors [25] to check for multicollinearity. Correction for multiple testing 
was not performed since dependent variables all measure the same underlying construct of disease 
severity. 
To examine whether comorbidity count or individual comorbid conditions independently inflated the 
patient global score, we repeated the above analyses for patient global and comorbidity count or 
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individual comorbidities, but additionally adjusting for other components of the ASDAS (3 questions 
and CRP). Throughout, model coefficients and 95% confidence intervals are displayed graphically 
with detailed results provided in online supplementary materials. Complete case analysis was used 
throughout with no imputation. 
Sensitivity analyses 
Some comorbidities, including heart failure, cancer, TB and demyelinating diseases, are routinely 
sought during the workup for TNF inhibitor therapy. It is therefore possible that these comorbidities 
are more prevalent in the biologic group due to differential ascertainment alone. We repeated all 
analyses in only the non-biologic cohort. For analyses of patient global (aim 2), successful 
adjustment for other components of ASDAS required adequate covariate overlap between 
comparison groups; extrapolating beyond overlap can introduce bias. We therefore matched 
patients on all covariates (gender, ever-smoking, education, IMD, quintiles of age and BMI, and 
tertiles of the three ASDAS questions and ln(CRP+1)) in sensitivity analyses (using coarsened exact 
matching [26]). All analyses were performed using Stata version 13. 
 
Results 
Among a total of 2687 participants, 2043 were included for analysis; exclusions were due to missing 
questionnaires (n=364), missing comorbidity data (n=6) and questionnaire outside the eligible 
window (n=274). The analysis population was predominantly male (67%) with mean age of 49.1 
years (SD 14.7). Classification criteria for AS was fulfilled by 1316 (65%). HLA-B27 status was 
available for 74% of participants and was positive in 79% of these cases. The mean BMI was 
27.7kg/m2. Current smoking was reported by 19% of participants, past smoking by 37% and 44% 
never smoked. 31% were in the biologic group (but not yet commenced on treatment). 
The prevalence of each comorbidity is shown in online supplementary figure S1. 44% of participants 
had at least one of the 14 comorbidities; 27% had 1 comorbidity, 10% had 2, and 5% had 3 or more 
(online supplementary figure S2). 
Table 1 compares participants with and without comorbidities. Those with comorbidities were older, 
had higher BMI and trend for lower educational attainment. Although there were more ever-
smokers in the group with comorbidities (63 v 50%), a larger proportion had quit (43 vs 32%). NSAID 
use in the preceding 6 months was less common among those with comorbidities. Participants with 
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comorbidity also had higher disease activity and other measures of disease severity, but similar 
levels of inflammatory markers. 









Mean age, years 45.3 (13.5) 53.9 (14.8) <0.001 
Males 742 (66%) 615 (69%) 0.078 
Meeting modified New York criteria 703 (62%) 613 (69%) 0.001 
Mean age at symptom onset, years 28.4 (11.3) 30.1 (12.3) 0.001 
Mean symptom duration, years 16.9 (13.4) 23.8 (15.3) <0.001 
HLA-B27 positive* 702 (80%) 471 (76%) 0.11 
Mean BMI, kg/m2 26.7 (4.9) 28.9 (6.0) <0.001 
Smoking 
status 
Never smoked 563 (50%) 323 (37%) <0.001 
Ex-smoker 355 (32%) 379 (43%) 
Current smoker 207 (18%) 181 (20%) 
Education Secondary school 335 (30%) 308 (35%) <0.001** 
Apprenticeship 92 (8%) 97 (11%) 
Further education 
college 
318 (28%) 289 (33%) 
University degree 275 (25%) 134 (15%) 
Further degree 102 (9%) 53 (6%) 
NSAID use in past 6 months 865 (77%) 596 (68%) <0.001 
DMARD use in past 6 months 103 (12%) 96 (15%) 0.13 
BASDAI, median (IQR) 4.4 (2.3, 6.6) 5.5 (3.3, 7.3) <0.001 
Spinal pain, median (IQR) 3.0 (1.0, 7.0) 5.0 (2.0, 8.0) <0.001 
ASDAS, mean (SD)* 2.2 (1.1) 2.4 (1.1) <0.001 
CRP (mg/dL), median (IQR)* 0.6 (0.2, 1.8) 0.6 (0.2, 2.0) 0.50 
ESR (mm/hr), median (IQR)* 10.5 (5.0, 23.0) 11.5 (5.0, 24.0) 0.28 
Fatigue, median (IQR) 14.0 (11.0, 18.0) 15.0 (11.0, 20.0) <0.001 
ASQoL, median (IQR) 7.0 (3.0, 12.0) 10.0 (5.0, 15.0) <0.001 
BASFI, median (IQR) 3.6 (1.5, 6.1) 5.7 (2.9, 7.9) <0.001 
BASMI, median (IQR)* 3.2 (2.0, 4.8) 4.4 (2.8, 6.0) <0.001 
Data shown as mean (SD) and n (%) unless otherwise indicated. 
*Not all variables had complete data; HLA-B27 was available for 74% of participants, 
BASMI 75%, ASDAS 78%, CRP 78%, ESR 39%. 
**non-parametric test for trend. 
IMD, index of multiple deprivation, 1=most deprived, 5=least deprived; IQR, interquartile 
range; BMI, body mass index; BASDAI, Bath AS disease activity index; BASFI, Bath AS 
functional index; BASMI, Metrology Index; ASQoL, AS quality of life questionnaire (range 
0-18, higher score indicates poorer quality of life); ASDAS, AS disease activity score; the 





Comorbidities and disease activity  
With comorbidity count as a continuous variable, each additional comorbidity was associated with 
higher BASDAI by 0.40 units (95%CI 0.27 to 0.52) and spinal pain by 0.53 (95%CI 0.37 to 0.68). Figure 
1 shows these relationships with comorbidity count as a categorical variable. For each additional 
comorbidity, ASDAS was higher by 0.09 units (95%CI 0.03 to 0.15). Those with 1 or 2 comorbidities 
did not have higher ASDAS than those with none in terms of statistical or clinical significance. 
Comorbidity count was not associated with log-transformed CRP (β=-0.03 (back-transformed effect 
size -0.03mg/dL); 95%CI -0.07 to 0.02) or log-transformed ESR (β=-0.03 (i.e., 0.97mm/hr); 95%CI -
0.12 to 0.06). 
Independent associations between each comorbid condition and disease activity are shown in Figure 
2. Participants with depression, heart failure and peptic ulcer diseases had consistently higher 
disease activity than those without each of these conditions. For example, participants with 
depression had 0.9-unit higher BASDAI and spinal pain than those without, accounting for covariates 
and all other comorbidities. Effect sizes were smaller for ASDAS. The only comorbidities associated 
with CRP and ESR were COPD and asthma, respectively; the back-transformed effect sizes for CRP 






Figure 1. Association between comorbidity count and disease activity. Results shown as adjusted 
model coefficients with 95% confidence intervals using participants with no comorbidities as the 
reference group; covariates were age, gender, BMI, smoking status, socioeconomic status and 
education. For example, participants with ≥3 comorbidities had 1.5-unit higher BASDAI and 0.38-unit 





Figure 2. Association between each comorbid condition and disease activity. Results shown as 
adjusted model coefficients with 95% confidence intervals compared to participants without each 
condition; covariates were age, gender, BMI, smoking status, socioeconomic status and education. 
For example, participants with heart failure (HF) had 1.7-unit higher BASDAI and 0.59-unit higher 
ASDAS than those without HF. IHD, ischaemic heart disease; HTN, hypertension; DM, diabetes 
mellitus; COPD, chronic obstructive pulmonary disease; PUD, peptic ulcer disease. 
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Comorbidities and other measures of disease severity 
Comorbidity count (as continuous variable) was significantly associated with worse fatigue (β=1.05; 
95%CI 0.76 to 1.33), quality of life (β=1.18; 95%CI 0.90 to 1.46) and functional impairment (β=0.55; 
95%CI 0.41 to 0.69). Effect size was smaller for BASMI (β=0.22; 95%CI 0.12 to 0.33) than BASFI. 
Figure 3 shows these relationships with comorbidity count as a categorical variable.  
Independent associations between each comorbid condition and the four disease severity measures 
are shown in Figure 4. Participants with heart failure, depression and peptic ulcer disease had 
consistently worse fatigue, quality of life and functional impairment than those without, accounting 
for covariates and all other comorbidities. Diabetics had worse function and quality of life, while 
participants with stroke had higher fatigue. The only comorbidities associated with CRP and ESR 
were COPD and asthma, respectively; the back-transformed effect sizes for CRP (0.5mg/dL) and ESR 
(0.7mm/hr) were not clinically meaningful. 
 
Figure 3. Association between comorbidity count and other measures of disease severity. Results 
shown as adjusted model coefficients with 95% confidence intervals using participants with no 
comorbidities as the reference group; covariates were age, gender, BMI, smoking status, 
socioeconomic status and education. For example, participants with ≥3 comorbidities had 2.0-unit 




Figure 4. Association between each comorbid condition and other measures of disease severity. 
Results shown as adjusted model coefficients with 95% confidence intervals compared to 
participants without each condition; covariates were age, gender, BMI, smoking status, 
socioeconomic status and education. IHD, ischaemic heart disease; HF, heart failure; HTN, 







Independent influence of comorbidity on the patient global component of ASDAS 
Patient global score increased (suggesting an increase in disease severity) with the number of 
comorbidities, but not independently of other ASDAS components (Figure 5). Depression, peptic 
ulcer and renal diseases were significantly associated with patient global, but not when additionally 
adjusting for other ASDAS components. 
 
Figure 5. Association between the patient global score and comorbidity. Results shown as model 
coefficients with 95% confidence intervals; covariates were age, gender, BMI, smoking status, 
socioeconomic status and education 
 
Results from both sensitivity analyses (see online supplementary materials) did not materially 






Patient-reported axSpA disease activity increased with the number of comorbidities in this cross-
sectional study. Unlike BASDAI and spinal pain, ASDAS was not associated with comorbidity count or 
individual comorbidities at a clinically meaningful effect size. Although patient global score was 
influenced by coexisting morbidities, they did not inflate ASDAS through the patient global score 
independently of other ASDAS components. When making treatment decisions, clinicians should be 
mindful of the potential impact of comorbidities on patient reported measures of disease activity 
and other measures of disease severity. Disease activity should be assessed using ASDAS when 
comorbidities are present.  
A key strength of this study is its large sample size from a broad range of rheumatology centres, for 
whom a wide range of disease measures were collected. Ascertainment of comorbidities was robust, 
using physician diagnoses from medical records. There were also limitations. Selection of 
comorbidities was not tailored for this secondary analysis; therefore some (e.g., neurological or 
infectious) comorbidities were not compared. However, included comorbidities were broadly 
representative of important diseases when compared to prior axSpA research [12]. Low prevalence 
of some conditions (e.g., heart failure, liver and demyelinating diseases) meant that their effect 
estimates had significant uncertainty. Severity (e.g., for heart failure) and more granular description 
(e.g., cancer type) for comorbidities were not available but would have provided useful information. 
Some comorbidities (TB, heart failure, cancer and demyelinating diseases) are of special interest 
when considering TNF inhibition therapy; they may be recorded more systematically in patients. 
However, restricting analyses to the non-biologic cohort did not meaningful change results. Lastly, 
Wording of the patient global question can be highly variable [27]. For example, the patient global in 
DAS28 can be worded to assess arthritis-related disease activity or global health (the recommended 
phrasing in RA is “Considering all the ways your arthritis has affected you, how do you feel your 
arthritis is today?”). In our data, patient global was specific to spondyloarthritis activity in the past 
week; therefore, other versions may not be equally robust the presence of comorbidities.  
Our results complement those from the ASAS-COMOSPA study, where comorbidity burden (assessed 
using RDCI) was associated with worse BASFI, quality of life (EuroQol) and work-related outcomes, 
despite using a slightly different list of comorbid conditions [5]. We additionally demonstrated that 
BASMI – a physician derived outcome often considered objective – is also significantly associated 
with comorbidity count, albeit with smaller effect sizes than BASFI. Importantly, we showed ASDAS 
to be comparatively robust to the presence of coexisting morbidities. Unlike BASDAI and spinal pain, 
the relationship between comorbidity count and ASDAS was not completely linear, which may be 
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explained by the weighting of ASDAS components. ASDAS was not significantly different between 
participants without comorbidities and those with 1 or 2, but the effect size was proportionately 
larger for ≥3 conditions. Nevertheless, a mean difference of 0.38 between those with ≥3 conditions 
and none is not clinically significant (meaningful change = 1.1). Our use of an unweighted 
comorbidity count was preferable, since RCDI was weighted for inpatient outcomes (i.e., mortality, 
hospitalization, disability, and costs) that may not be appropriate to study axSpA-specific measures. 
It also allowed us to examine the relationship between comorbidity and outcomes in more detail: 
depression, diabetes, heart failure, peptic ulcer and renal diseases were the most significant 
contributing conditions.  
Neither the ASAS-COMOSPA nor our cross-sectional study could establish causal relationships. For 
example, heart failure is likely to cause functional impairment, but participants with heart failure 
may also have reduced access to treatment (NSAIDs and TNFi) to reduce functional decline. Similarly, 
renal and peptic ulcer diseases can be contraindications for symptomatic control with NSAIDs, but 
may also result from long-term need for NSAIDs due to active disease. These are limitations arising 
from the cross-sectional design and lack of historical NSAID data. Results from our analysis do, 
however, suggest that outcomes such as ASDAS and BASMI are less influenced by comorbidities than 
patient-reported measures. 
In RA, patient global increased with the number of comorbidities, independently of tender/swollen 
joint count, CRP and physician global [11]. Among axSpA participants in this study, patient global was 
significantly associated with comorbidity count, but not independently so when adjusting for other 
ASDAS components. This further reassures and supports the use of ASDAS, particularly when 
comorbidities are present and likely to influence other outcome measures. Further longitudinal 
studies are needed to assess whether comorbidities influence treatment response as measured by 
different outcomes. Longitudinal studies on comorbidities as “exposure” (rather than outcome) in 
axSpA are scarce. Preliminary results from the BSRBR-AS suggests that comorbidity may be one of 
very few potentially modifiable predictors of treatment response [28]. 
In summary our results suggest that patient-reported axSpA measures are influenced by coexisting 
morbidities. This is important for routine practice as around half of all patients have at least one 
comorbidity. ASDAS seems to be less vulnerable to the presence of comorbidities. ASDAS was not 
disproportionately inflated by the patient global score as was shown for DAS28 in rheumatoid 
arthritis. In routine clinical practice, clinicians should consider additionally collecting ASDAS to assess 
disease activity in patients with multiple comorbidities, including but not limited to depression. 
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Further studies should examine the impact of comorbidity burden on longitudinal disease severity 
and response to treatment. 
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